Psilocybin
Psychedelic Drug Library Earns Psilera U.S. Patent
The company formulates synthetic psychedelic compounds for mental health treatments.
The post Psychedelic Drug Library Earns Psilera U.S. Patent appeared…
Tampa-based biopharmaceutical company Psilera received a notice of allowance from the U.S. Patent and Trademark Office for its patent application on new mental health treatments for home use.
The patent provides protections for the company’s expansive drug library, it said, resulting from “years of dedicated research and development to curate a diverse collection of compounds with disease modifying potential for mental health disorders,” the company said in a statement Wednesday.
CEO Chris Witowski said the approval represents “one of the most significant IP allowances of a next-generation psychedelic compound library.”
He added, “Securing this patent is not just a legal milestone; it’s a testament to our relentless pursuit of innovation and our commitment to shaping a brighter future for patients with unmet needs.”
Studies indicate that Psilera’s drug candidates have quick efficacy for various psychiatric and addiction disorders, the company said.
“Furthermore, Psilera has de-risked multiple drug classes in this IP allowance which have shown improved safety profiles and fewer side effects than current psychedelics,” it added.
The patent follows Psilera’s prior milestone related to formulas for dimethyltryptamine (DMT) and a psilocybin-like drug, psilacetin. The company said it aims to create therapies that limit hallucinogenic effects to cater to a broader patient base.
The post Psychedelic Drug Library Earns Psilera U.S. Patent appeared first on Green Market Report.
psilocybin dmt dimethyltryptamine psychedelic hallucinogenic psychedelics psilera research
-
Psychedelics1 week agoCybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin5 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics4 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days agoOptimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research